Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader.

Androgen receptor (AR) signaling is the principal driver of prostate cancer, and drugs that target this pathway (e.g., abiraterone and enzalutamide) are standard treatments for metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer (mCRPC).

Crowding effects on the structure and rheology of ultrasoft PNIPAM-PEGMA copolymer microgels.

We investigate the link between the internal microstructure of poly(-isopropylacrylamide)-poly(ethylene glycol) methyl ether methacrylate (PNIPAM-PEGMA) microgels, their bulk moduli and the rheological response and structural arrangement in dense suspensions. The low degree of crosslinking combined with the increased hydrophilicity induced by the presence of PEGMA results in a diffuse, star-like density profile of the particle and very low values of the bulk modulus in dilute conditions, as determined by small angle neutron scattering (SANS). The ultrasoft nature of the particle is reflected in the changes of the structural arrangement in dense suspensions, which evidence a strong deswelling and a sharp rise of the bulk modulus at moderate packing fractions.

Sex-specific Associations between Left Ventricular Remodeling at MRI and Long-term Cardiovascular Risk.

Background Left ventricular mass (LVM) is an established marker of cardiovascular risk; however, long-term follow-up studies in individuals with low to intermediate risk are lacking. Purpose To assess the sex-specific association of LVM measured with cardiac MRI with cardiovascular outcomes in those with a less than 20% 10-year risk of cardiovascular disease (CVD). Materials and Methods A total of 1528 volunteers older than 40 years of age with no history of CVD, a 10-year risk of CVD of less than 20%, and a B-type natriuretic peptide level greater than their sex-specific median underwent cardiac MRI between June 2008 and February 2013 as part of the Tayside Screening for Cardiac Events, or TASCFORCE, prospective study.

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase-CYP substrates.

Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug-metabolizing enzymes such as cytochrome P450s (CYPs). As such, the lack of established framework for quantitative translation of the clinical pharmacologic correlates of AO-mediated clearance represents an unmet need. This study aimed to evaluate the utility of physiologically based pharmacokinetic (PBPK) modeling in the development of AO and dual AO-CYP substrates.